Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10836033 | 0.87 | TSHR (0.36) | TSHRALDH1A1LMNA | |
| SCHEMBL8060298 | 0.85 | TSHR (0.50) | TSHRALDH1A1TDP1LMNASLC1A3 | |
| SCHEMBL3199611 | 0.85 | — | — | |
| SCHEMBL28364887 | 0.84 | TSHR (0.40) | TSHRALDH1A1TDP1LMNA | |
| SCHEMBL27105836 | 0.84 | LMNA (0.42) | TSHRALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL1668244 | 0.83 | TSHR (0.42) | TSHRALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL28368639 | 0.82 | ALDH1A1 (0.44) | TSHRALDH1A1LMNA | |
| SCHEMBL15158732 | 0.82 | TSHR (0.53) | TSHRALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL12059090 | 0.81 | TSHR (0.48) | TSHRALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL18231993 | 0.81 | TSHR (0.48) | TSHRALDH1A1CACNA2D1CACNB3CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140213680-A1 | POLYSULFIDE POLYOLS, THEIR PRODUCTION AND USE | BASF SE (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | TSHR 1410/4885ALDH1A1 1721/4885CACNA2D1 1448/4885 |
| US-20140213680-A1 | POLYSULFIDE POLYOLS, THEIR PRODUCTION AND USE | STS, PUF60, MPST | TSHR 4356/4885ALDH1A1 3175/4885CACNA2D1 4712/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TSHR 1410/4885ALDH1A1 1721/4885CACNA2D1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.